EICHORPublic-registry site landscape for NCT05162365, “A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19”, a COVID-19 study sponsored by Innovent Biologics (Suzhou) Co. Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05162365 (registry record) |
| Study title | A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Condition(s) | COVID-19 |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 19 |
| Intervention(s) | IBI314 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05162365.
Eichor generates a preliminary site-risk snapshot for NCT05162365 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
